The announcement of  TopAlliance Biosciences, a wholly-owned subsidiary of Junshi Biosciences of FDA approval of LOQTORZI™ (toripalimab-tpzi), marks a success in the treatment of nasopharyngeal carcinoma (NPC). This treatment, the first and only FDA approved for this condition, will now be available in Central America thanks to Lanco Medical Group’s robust platform and regional presence, ensuring this vital treatment is no longer needed.

TopAlliance Biosciences trusted Lanco Medical Group’s ability to navigate operational and regulatory complexity in Central America, ensuring that LOQTORZI™ can have the maximum impact possible, saving more lives across broader, more effective access.

This is a significant step in the right direction in our ongoing commitment to transforming healthcare and improving quality of life in Latin America, aligned with our vision of ensuring access to sustainable, advanced and cutting-edge treatments for all patients from region.